Physician profile
John C Cross
NPI 1922061670
$4,186.19
in general payments reported to CMS, 2019-2025
19 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,387 · 2020: $206 · 2021: $518 · 2022: $234 · 2023: $314 · 2024: $286 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,581.43 | 2019-2025 | Precision 1, Dailies, Precision 7 |
| Bausch & Lomb Americas INC. | $400.32 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Sun Pharmaceutical Industries INC. | $203.35 | 2019-2024 | |
| Maculogix, INC. | $181.69 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $168.26 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $118.36 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $92.44 | 2022 | |
| Coopervision INC. | $80.81 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $77.12 | 2024-2025 | Xdemvy |
| Abbvie INC. | $73.43 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $46.36 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $33.17 | 2020-2022 | |
| Shire North American Group INC | $23.21 | 2019 | |
| Sight Sciences, INC. | $20.44 | 2020 | |
| Dompe US, INC. | $19.82 | 2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.52 | 2024 | Tepezza |
| Allergan, INC. | $19.50 | 2021 | |
| Abb Con-Cise Optical Group LLC | $13.63 | 2019 | |
| Derma Sciences, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.